Friday, January 3, 2014
The American Diabetes Association and Eli Lilly have announced the recipients of the American Diabetes Association and Lilly Clinical Research Award: Diabetes Care in Older Adults, a three-year collaborative research program aimed at better understanding diabetes care in older adults. The program, made possible through $1.2 million in funding from Lilly Diabetes, is awarding two clinical grants that will be directed, managed and overseen by the Association.
Kester Capital, the European private equity arm of Greenhill & Co., has sold its interest in Chiltern in a deal valuing the company at $223.4 million. The exit comes as Chiltern announces the consolidation of existing investors, led by Sir Douglas Myers. The transaction has generated a return of over two times capital and a 25% IRR for Kester Capital funds.
ideaPoint, a provider of partnering and collaboration systems for global enterprises, has announced the availability of a new portal providing a secure system for researchers to request access to anonymized, patient-level clinical trial data provided by sponsors (clinicalstudydatarequest.com). Study sponsors who have committed to provide data through the site currently include Boehringer Ingelheim, GlaxoSmithKline, Roche, Sanofi and ViiV Healthcare.
Cyprotex, a specialist ADME-Tox CRO, has acquired CeeTox, a division of North American Science Associates. CeeTox, based in Kalamazoo, Mich., is a CRO specializing in the provision of in vitro toxicological assays and screening data, principally to the Cosmetic and Personal Care Industries. Founded in 2003, CeeTox was acquired in 2005 by NAMSA, a medical research organization supplying expert consulting, clinical and laboratory services to medical device, IVD and biologics manufacturers. NAMSA retains a license for applying CeeTox’s in vitro toxicology experience to medical device testing.
A collaborative pharmaceutical project focused on improving the pathway for developing pediatric formulations has been given the go-ahead after successfully securing an innovation grant.
The endorsement by the E.U. Committee of Permanent Representatives of the political agreement reached by the Lithuanian E.U. Council Presidency and the European Parliament, on the compromise text of the proposed E.U. Clinical Trials Regulation looks set to not deliver on the initial goal set by the European Commission (E.C.) when it launched the process in July 2012 of making the E.U. a more attractive location to conduct clinical trials.